16 news items
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CRBU
DTIL
TGTX
13 May 24
of its kind potential treatment for m.3243-associated PMM by targeting mutant mitochondrial DNA. Mitochondrial diseases are the most common hereditary
HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $49
TGTX
2 May 24
HC Wainwright & Co. analyst Edward White maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $45 to $49.
Ladenburg Thalmann Maintains Buy on TG Therapeutics, Raises Price Target to $40
TGTX
2 May 24
Ladenburg Thalmann analyst Matthew Kaplan maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $39 to $40.
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
AKAN
AMD
ASTE
1 May 24
to Neutral and lowered the price target from $36 to $13.
Leggett & Platt, Incorporated
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
TGTX
1 May 24
), for the treatment of autoimmune disorders and all other non-oncology indications 2024 Updated Target U.S. BRIUMVI Guidance
xg98zo0e01mzlby9jbd70d0hlj1pdehhns5ze6fek136eu2bta1iznqb
TGTX
18 Apr 24
HC Wainwright & Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy and maintains $45 price target.
0whj04otn3y9u52ti48hwp468unf86l7sankgxpya
TGTX
18 Apr 24
JP Morgan analyst Eric Joseph reiterates TG Therapeutics (NASDAQ:TGTX) with a Overweight and maintains $25 price target.
r1zr42bi0bdej78ew5f4r0plm7ae7jpxc9xylnovkp6q726l6ylpku6tlk
TGTX
18 Apr 24
® (ublituximab-xiiy) 150 mg/6 mL Injection for IVBRIUMVI is a novel monoclonal antibody that targets a unique epitope
wg22d 3o7k
TGTX
15 Apr 24
monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important
6t603z4xrhmys0mcl7f0fvga141bm6s81bls617sn10kg38d51
CRBU
DTIL
TGTX
27 Mar 24
efficacy and safety for the final clinical candidate including no detectable off-target editing at maximal on-target editing dose
9itoqt1ezo6scglxr r8loo9g17bjvqtwgeva8rx0alhpjy7kklu
TGTX
8 Mar 24
BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IVBRIUMVI is a novel monoclonal antibody that targets a unique epitope
76mg0p4axsznjovoaaxq5qnzut6rvmkavt59mmrc2eyrvan2 tfg
TGTX
1 Mar 24
HC Wainwright & Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy and maintains $45 price target.
4zet273jw4p14w4vmgjlnjynk31ncidix5ip4i777gok0kq3djeb54fi
TGTX
1 Mar 24
). ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IVBRIUMVI is a novel monoclonal antibody that targets
qvmuxtgt71agcw8td3xb5di3obiudd
TGTX
29 Feb 24
Goldman Sachs analyst Corinne Jenkins maintains TG Therapeutics (NASDAQ:TGTX) with a Neutral and raises the price target from $12 to $13.
law02rwocqm4glzwn9wup82mp1v8btk qm1
TGTX
28 Feb 24
HC Wainwright & Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy and maintains $45 price target.
v52peb1a
TGTX
28 Feb 24
exceeded our expectations, and we ended the year with approximately $89 million in U.S. net revenue and provided a BRIUMVI U.S. net revenue target of $220
- Prev
- 1
- Next